In a significant boost for the future of precision medicine, BullFrog AI (NASDAQ: BFRG) has successfully raised $3,130,000 to further its groundbreaking initiatives in drug discovery. As a trailblazing technology-enabled life science company, BullFrog AI is harnessing the power of advanced artificial intelligence (AI) to transform the landscape of drug development, which has long been plagued by high costs, lengthy timelines, and a staggering 90% failure rate for therapeutic products. Their innovative platform, bfLEAP™, is at the forefront of this revolution, utilizing advanced graph analytic AI technologies to accelerate and de-risk clinical development processes. This funding will significantly enhance BullFrog AI's capabilities in identifying new therapeutic targets, optimizing clinical trials, and effectively repurposing existing drugs for new indications, ultimately aiming to bring life-saving therapies to the market more efficiently. With the ability to provide explainable AI insights through their interactive network models, BullFrog AI is paving the way for a new era in drug development—one that empowers researchers and stakeholders to make informed decisions grounded in robust data. With a high-powered team of industry experts and a pipeline of in-licensed assets ready for clinical development, BullFrog AI is determined to redefine the future of healthcare. Join us as we leap into the next generation of drug development, making each day count for patients in need of timely treatments.








